![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
May 08, 2024
昌郁医药选择性TRPM8受体拮抗剂XG2002胶囊I期临床研究首组受试者入组完成
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
April 08, 2024
昌郁医药宣布XG005中国膝骨关节炎II期临床试验完成目标受试者入组
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
March 11, 2024
昌郁医药创新镇痛产品XG2002 临床试验获得澳大利亚HREC批准
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
December 20, 2023
昌郁医药全新靶点镇痛产品XG2002澳大利亚I期临床研究正式启动
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
August 23, 2023
昌郁医药宣布XG005镇痛在研产品完成在美国的手术后疼痛临床2b/3期试验首例患者入组
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
April 26, 2023
昌郁医药宣布XG004透皮凝胶治疗膝骨关节炎(OA)疼痛的1b/2a临床试验获得阳性结果
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
December 22, 2022
昌郁医药首席医学官姜广良博士参加欧洲疼痛临床试验大会并做主题演讲
![fda fda](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/fda-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpg)
December 13, 2022
昌郁医药宣布XG005中国II期临床试验完成首例患者入组
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
November 21, 2022
昌郁医药姜广良博士参加世界疼痛医学大会
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
July 26, 2022
昌郁医药创新镇痛产品XG004透皮凝胶正式启动澳大利亚1b/2a期临床试验
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
March 04, 2022
世界知名的疼痛领域创新药研发专家郑国柱博士加入昌郁医药任职首席药物研发官兼高级副总裁(CDO)
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
November 04, 2021
昌郁医药完成4000万美元C轮超额融资,加速疼痛和神经管线布局
![xgene logo xgene logo](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/xgene-logo-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
October 04, 2021
姜广良博士加入昌郁医药任职首席医学官(CMO)
![項目啟動會 項目啟動會](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
September 29,2021
昌郁医药创新镇痛产品XG005 I 期临床桥接试验启动会正式举行
![RaQUA2 RaQUA2](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/RaQUA2-pfy8zfloswa1nc19agoolt9h5jlrpt4g9mhv9fu2zg.png)
September 22,2021
全球独家!昌郁医药与RaQualia Pharma就全新镇痛产品签署授权协议
![fda fda](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/fda-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpg)
April 22,2020
XG005新药上巿的申请,遵循
505(b)(1)法规的监管
![News_04May2019 News_04May2019](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/News_04May2019-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpeg)
May 4, 2019
昌郁医药公司完成B+轮融资
![News_25Oct2018 News_25Oct2018](https://xgenepharm.com/wp-content/uploads/elementor/thumbs/News_25Oct2018-pfy8zgjizqbbyxzw4z3b6b0xqxh4xi86lr5cqpsot8.jpg)
October 25, 2018
昌郁医药公司完成两千万美元 B轮融资